Serum TGF-β1 as a biomarker for type 2 diabetic nephropathy: A meta-analysis of randomized controlled trials

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Mou, Xin ^a   Zhou, Di Yi ^a   Zhou, Dan Yang ^a   Ma, Jing Ru ^b   Liu, Ying Hui ^a   Chen, Hui Ping ^a   Hu, Yong Bin ^a   Shou, Cheng Min ^a   Chen, Jia Wei ^a   Liu, Wen Hong ^b   Ma, Guo Ling ^a  

^a Hangzhou Red Cross Hospital   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; BIOLOGICAL MARKER; TGFB1 PROTEIN, HUMAN;

ARTICLE; CLINICAL EFFECTIVENESS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; UPREGULATION; BLOOD; FEMALE; MALE;

BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84960504139     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149513     Document Type: Article

References (31)

1. Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, et al. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States Preface. Am J Kidney Dis. 2015; 66(1):SVII-SVII. doi: 10.1053/j.ajkd.2015.05.001 WOS:000356729900001. PMID: 26111994
2. Gilg J, Pruthi R, Fogarty D. UK Renal Registry 17th Annual Report: Chapter 1 UK Renal Replacement Therapy Incidence in 2013: National and Centre-specific Analyses. Nephron. 2015; 129:1-29. doi: 10.1159/000370271 WOS:000350761700002.
3. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk-Is albumin excretion rate sufficient? Diabetes. 2000; 49(9):1399-408. doi: 10.2337/diabetes.49.9.1399 WOS:000089062800001. PMID: 10969821
4. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007; 18 (4):1353-61. doi: 10.1681/asn.2006080872 WOS:000245524300038. PMID: 17329575
5. Miner JH. Building the glomerulus: a matricentric view. Journal of the American Society of Nephrology: JASN. 2005; 16(4):857-61. Epub 2005/02/25. doi: 10.1681/ASN.2004121139 PMID: 15728777.
6. Lehmann R, Schleicher ED. Molecular mechanism of diabetic nephropathy. Clinica chimica acta; international journal of clinical chemistry. 2000; 297(1-2):135-44. Epub 2000/06/08. PMID: 10841915.
7. Ning L, Kurihara H, de Vega S, Ichikawa-Tomikawa N, Xu Z, Nonaka R, et al. Laminin alpha1 regulates age-related mesangial cell proliferation and mesangial matrix accumulation through the TGF-beta pathway. Am J Pathol. 2014; 184(6):1683-94. Epub 2014/04/12. doi: 10.1016/j.ajpath.2014.02.006 PMID: 24720953; PubMed Central PMCID: PMC4044709.
8. Tas F, Yasasever CT, Karabulut S, Tastekin D, Duranyildiz D. Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer. Tumor Biol. 2015; 36 (3):2097-103. doi: 10.1007/s13277-014-2817-9 WOS:000351884000085.
9. Ni BB, Li B, Yang YH, Chen JW, Chen K, Jiang SD, et al. The effect of transforming growth factor beta 1 on the crosstalk between autophagy and apoptosis in the annulus fibrosus cells under serum deprivation. Cytokine. 2014; 70(2):87-96. doi: 10.1016/j.cyto.2014.07.249 WOS:000344423900002. PMID: 25127907
10. Lee YM, Kim SS, Kim HA, Suh YJ, Lee SK, Nahm DH, et al. Eosinophil inflammation of nasal polyp tissue: Relationships with matrix metalloproteinases, tissue inhibitor of metalloproteinase-1 and transforming growth factor-beta 1. Journal of Korean medical science. 2003; 18(1):97-102. WOS:000181346100018. PMID: 12589095
11. Schilter H, Cantemir-Stone CZ, Leksa V, Ohradanova-Repic A, Findlay AD, Deodhar M, et al. The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-beta 1 pathway in human lung fibroblasts. Immunology letters. 2015; 165(2):90-101. doi: 10.1016/j.imlet.2015.04.003 WOS:000356195300005. PMID: 25929803
12. Fibrosis: TGF-beta signalling and renal fibrosis. Nature reviews Nephrology. 2015; 11(5):254. doi: 10.1038/nrneph.2015.45 MEDLINE:25825081.
13. Lee SJ, Kang JG, Ryu OH, Kim CS, Ihm SH, Choi MG, et al. Effects of alpha-lipoic acid on transforming growth factor beta1-p38 mitogen-activated protein kinase-fibronectin pathway in diabetic nephropathy. Metabolism: clinical and experimental. 2009; 58(5):616-23. Epub 2009/04/21. doi: 10.1016/j.metabol. 2008.12.006 PMID: 19375583.
14. McKnight AJ, Savage DA, Patterson CC, Sadlier D, Maxwell AP. Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy. BMC medical genetics. 2007; 8:5. Epub 2007/02/27. doi: 10.1186/1471-2350-8-5 PMID: 17319955; PubMed Central PMCID: PMC1808054.
15. Russo LM, del Re E, Brown D, Lin HY. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor. Diabetes. 2007; 56(2):380-8. Epub 2007/01/30. doi: 10.2337/db06-1018 PMID: 17259382.
16. Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-kappaB and transforming growth factor-beta1/Smad3 in diabetic nephropathy. Exp Biol Med (Maywood). 2010; 235(3):383-91. Epub 2010/04/21. doi: 10.1258/ebm. 2009.009218 PMID: 20404057; PubMed Central PMCID: PMC3057137.
17. Zhang Xuejun LP, Bao Mingjin, Chen Ping, Lv Yuechan. Clinical evaluation of serum TGFβ1 in patients with type II diabetic nephropathy. Liaoning Journal of Practical Diabetology. 2004; 12(1).
18. Ju Haibing Gp, Li Jing, Shen Feifei, Shu Zizheng. Changes in serum TGFβ1 in type 2 diabetic patients. Chinese Journal of Pathophysiology. 2001; 17(11).
19. Wu Xingfu CL. Clinical significance of determination of serum Cystastin C (Cys C), Transforming Growth Factor (TGF-β1) and Hepatocyte Growth Factor (HGF) levels in patients with DM2 complicated with nehpropathy. J of Radioimmunology. 2011; 24(1).
20. Changxin F. Clinical significance of determination of serum cystatin C, transforming growth factor beta1 and urine microalbumin levels in patients with DM2 nephropathy. J of Radioimmunology. 2007; 20(5).
21. Zhen L. Detection and analysis fro inflammation-associated factors in patients with type 2 diabetic nephropathy. Lab Med Clin. 2011; 8(8).
22. Liu Ruiji LL. The serum level of hepatocyes growth factor and transforming growth factor-β1 in type 2 diabetic nephropathy patients in clinic. Hebei Medical Journal. 2011; 33(12).
23. Yaping W. Clinical significance of determination of changes of plasma ET and serum TGFβ1, VEGF levels in patients with 2-type diabetes. Journal of Radioimmunology. 2008; 21(6).
24. Xie Hongfang PL. Clinical significance of determination of serum Collagen Type IV (IV-C) and Transforming Growth Factor Beta1(TGF-β1) levels in patients with diabetic nephropathy. J of Radioimmunology. 2006; 19(5).
25. Weikang Z. Clinical significance of determination of transforming growth factor beta1, tumor necrosis factor alpha and urine microalbumin levels in patients with DM2 nephropathy. J Clin Res. 2008; 25(6).
26. Kondo S, Kagami S, Urushihara M, Kitamura A, Shimizu M, Strutz F, et al. Transforming growth factorbeta 1 stimulates collagen matrix remodeling through increased adhesive and contractive potential by human renal fibroblasts. Biochim Biophys Acta-Mol Cell Res. 2004; 1693(2):91-100. doi: 10.1016/j. bbamcr.2004.05.005 WOS:000223578900002.
27. Yang Q, Xie R-j, Yang T, Fang L, Han B, Zhang G-z, et al. Transforming growth factor-beta 1 and smad4 signaling pathway down-regulates renal extracellular matrix degradation in diabetic rats. Chinese Medical Sciences Journal. 2007; 22(4):243-9. BIOABS:BACD200800117761. PMID: 18246672
28. Sharma K, Jin YL, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996; 45(4):522-30. WOS:A1996UM98100020. PMID: 8603776
29. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-de la Cruz MC, Hong SW, Isono M, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. P Natl Acad Sci USA. 2000; 97(14):8015-20. doi: 10.1073/pnas.120055097 WOS:000088048400065.
30. Zhou TB, Jiang ZP, Qin YH, Drummen GPC. Association of transforming growth factor-beta 1 T869C gene polymorphism with diabetic nephropathy risk. Nephrology. 2014; 19(2):107-15. doi: 10.1111/nep. 12176 WOS:000330853000008. PMID: 24428217
31. Zhang J, Guan YL, Xiao Y, Zhang XW. A meta-analysis of the association of G915C, G800A, C509T gene polymorphism of transforming growth factor-beta 1 with diabetic nephropathy risk. Ren Fail. 2014; 36(2):321-6. doi: 10.3109/0886022x.2013.832320 WOS:000333168000028. PMID: 24060183